XLIFE SCIENCES AG Financials Xlife Sciences AG BOERSE MUENCHEN
Equities
XLS
CH0461929603
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.8 EUR | -0.48% |
|
-7.52% | -3.69% |
| Apr. 23 | Xlife Sciences Posts Higher FY23 Profit; Revenue Falls | MT |
| Feb. 29 | Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 |
|---|---|---|---|
| Capitalization 1 | 156.9 | 279 | 195.6 |
| Enterprise Value (EV) 1 | 216.9 | 335.2 | 260.8 |
| P/E ratio | 14.9 x | 24 x | -52 x |
| Yield | - | - | - |
| Capitalization / Revenue | 153 x | 282 x | 245 x |
| EV / Revenue | 211 x | 339 x | 326 x |
| EV / EBITDA | -43.7 x | -78.4 x | -65.2 x |
| EV / FCF | -46.3 x | - | -52.2 x |
| FCF Yield | -2.16% | - | -1.92% |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 5,284 | 5,590 | 5,703 |
| Reference price 2 | 29.70 | 49.90 | 34.30 |
| Announcement Date | 4/20/23 | 2/29/24 | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net sales 1 | 0.3968 | 0.8061 | 1.028 | 0.9884 | 0.8 |
| EBITDA 1 | -2.964 | - | -4.961 | -4.278 | -4 |
| EBIT 1 | -3.025 | - | -20.98 | -20.31 | -4.19 |
| Operating Margin | -762.31% | - | -2,041.2% | -2,054.54% | -523.75% |
| Earnings before Tax (EBT) 1 | 21.26 | - | 4.039 | 4.534 | -5 |
| Net income 1 | 21.62 | 53.42 | 14.31 | 14.88 | -4 |
| Net margin | 5,449.53% | 6,627.03% | 1,392.26% | 1,505.33% | -500% |
| EPS 2 | - | - | 2.000 | 2.080 | -0.6600 |
| Free Cash Flow 1 | -0.4577 | - | -4.688 | - | -5 |
| FCF margin | -115.35% | - | -456.01% | - | -625% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/31/21 | 4/29/22 | 4/20/23 | 2/29/24 | - |
1CHF in Million2CHF
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net Debt 1 | 50.8 | - | 60 | 56.2 | 65.2 |
| Net Cash position 1 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -17.15 x | - | -12.1 x | -13.14 x | -16.3 x |
| Free Cash Flow 1 | -0.46 | - | -4.69 | - | -5 |
| ROE (net income / shareholders' equity) | 19% | - | - | - | - |
| ROA (Net income/ Total Assets) | 12.7% | - | - | - | - |
| Assets 1 | 169.9 | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 0.08 | - | 1 |
| Capex / Sales | - | - | 7.8% | - | 125% |
| Announcement Date | 3/31/21 | 4/29/22 | 4/20/23 | 2/29/24 | - |
1CHF in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
34.3
CHF
Average target price
68
CHF
Spread / Average Target
+98.25%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- XLS Stock
- XLS Stock
- Financials Xlife Sciences AG
